TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23938028

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous dexamethasone
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 1350
Study: 21810649

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate) at a target dose of 10 to 12 mg per kilogram of body weight per day for 24 months
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 19265311

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg combined with dexamethasone 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 50
Study: 17040215

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg single dose) taken 12 hours prior to melatonin intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg single dose) taken 24 hours prior to melatonin intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Abstinence from caffeine for 24 hours prior to melatonin intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Melatonin as a probe drug
Number of subjects: 12
Study: 15124980

Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevert, ARL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 50 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11585005

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nateglinide + Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 9161648

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial gel containing cetrimide, bacitracin, and polymyxin B sulfate
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: COMPARATOR
Intervention: Povidone iodine antiseptic cream
Number of subjects: 177
Study: 7967362

Group type: EXPERIMENTAL
Intervention: Torasemide alone (50 mg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Torasemide + Butizid (20 mg i.v.)
Number of subjects: 10
Study: 3307643

Group type: EXPERIMENTAL
Intervention: 20 micrograms of desmopressin given through a nasal pipette
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 micrograms of desmopressin tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desmopressin (both oral and nasal)
Number of subjects: 30
Study: 31786349

Group type: EXPERIMENTAL
Intervention: Hysterectomy with salpingectomy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Hysterectomy without salpingectomy (control group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 86
Study: 30098126

Group type: EXPERIMENTAL
Intervention: Inulin-propionate ester (IPE) 20 g/d for 42 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inulin control
Number of subjects: 18
Study: 27381489

Group type: EXPERIMENTAL
Intervention: dGEMRIC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 32
Study: 25271185

Group type: EXPERIMENTAL
Intervention: 25 mg i.m. ketamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: 10 mg i.m. morphine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23710492

Group type: EXPERIMENTAL
Intervention: Natamycin (5%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Natamycin (5%)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Voriconazole (1%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Number of subjects: 368

Group type: COMPARATOR
Intervention: Voriconazole (1%)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Natamycin (5%) for Fusarium cases
Number of subjects: 368

Group type: COMPARATOR
Intervention: Voriconazole (1%) for non-Fusarium cases
Number of subjects: 368
Study: 21655762

Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 56
Study: 18638649

Group type: EXPERIMENTAL
Intervention: Therapy as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reparations that adult life offers
Number of subjects: 0
Study: 17276952

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Risedronate 5 mg daily
Number of subjects: 30
Study: 15166648

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11722525

Group type: EXPERIMENTAL
Intervention: 5‐0 monofilament sutures
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Tapes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 79
Study: 9159833

Group type: EXPERIMENTAL
Intervention: Peritoneal sclerosis patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 8431570

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 1 g/patient
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study: 3298752

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 37.5 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Carteolol (CAR) 15 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Captopril (CAP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Carteolol (CAR)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) and Carteolol (CAR)
Number of subjects: 39
Study: 29807307

Group type: EXPERIMENTAL
Intervention: Combo stent (dual-therapy CD34 antibody-covered sirolimus-eluting stent)
Number of subjects: 3140

Group type: COMPARATOR
Intervention: Orsiro stent (sirolimus-eluting stent)
Number of subjects: 3140
Study: 26935233

Group type: EXPERIMENTAL
Intervention: Family/Friends (F/F) support with self-care
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Family/Friends (F/F) involvement in the self-care intervention
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Emotional support from Family/Friends (F/F)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Perceived F/F involvement in the self-care intervention
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Perception of F/F support
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: F/F perceived involvement in the self-care intervention
Number of subjects: 189
Study: 24852386

Group type: EXPERIMENTAL
Intervention: Coccygeal movement test (CMT)
Number of subjects: 24
Study: 22676921

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of oxytocin 10 IU via Uniject™ by Community Health Officers within one minute of delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (deliveries which do not receive the prophylactic intervention)
Number of subjects: 0
Study: 20028969

Group type: EXPERIMENTAL
Intervention: Low-insulin high-glucose (LIHG; variable insulin, BG of 7-9 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-insulin high-glucose (HIHG; insulin 2.0 mU.kg(‐1).min(‐1) plus insulin requirement from study 1, BG of 7-9 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-insulin low-glucose (HILG; insulin 2.0 mU.kg(‐1).min(‐1) plus insulin requirement from study 1, BG of 4-6 mmol/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age-matched healthy subjects receiving two-step euglycemic hyperinsulinemic clamps)
Number of subjects: 0
Study: 18400964

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU Q4W
Number of subjects: 262

Group type: COMPARATOR
Intervention: Epoetin alfa 20,000 IU Q2W
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 IU QW
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 IU Q4W
Number of subjects: 262
Study: 12231591

Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic agents
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 1138
Study: 9714962

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture on permucosal dental implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overdenture on a transmandibular implant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New dentures after preprosthetic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: New dentures only
Number of subjects: 0
Study: 7848789

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean final daily dose 2.9 mg)
Number of subjects: 4809

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 4809
Study: 2973598

Group type: EXPERIMENTAL
Intervention: Ceftazidime 3g/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ceftazidime 3g/day + Amikacin or Vancomycin
Number of subjects: 21
Study: 30293128

Group type: EXPERIMENTAL
Intervention: Functional behavior-based cognitive behavior therapy (Fb-CBT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 37
Study: 31109342

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM) using FreeStyle Libre
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitored blood glucose (SMBG) testing (usual care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGM acceptability
Number of subjects: 0
Study: 28601705

Group type: EXPERIMENTAL
Intervention: 4-ABVD-IFRT
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: 4-BEACOPPbaseline-IFRT
Number of subjects: 808

Group type: COMPARATOR
Intervention: 6-ABVD-IFRT
Number of subjects: 808
Study: 26525623

Group type: EXPERIMENTAL
Intervention: Original memantine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Generic medication (memantal)
Number of subjects: 50
Study: 22968256

Group type: EXPERIMENTAL
Intervention: Low-dose ALN (70 mg every two weeks)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Standard-dose ALN (70 mg weekly)
Number of subjects: 639
Study: 21337878

Group type: EXPERIMENTAL
Intervention: Brisk TIL response
Number of subjects: 515

Group type: COMPARATOR
Intervention: Non-brisk TIL response
Number of subjects: 515
Study: 18237377

Group type: EXPERIMENTAL
Intervention: Telephone or postal questionnaire completion
Number of subjects: 765

Group type: COMPARATOR
Intervention: Postal questionnaire completion only
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Telephone completion
Number of subjects: 765

Group type: COMPARATOR
Intervention: Postal administration
Number of subjects: 765
Study: 17032661

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 27
Study: 12610178

Group type: EXPERIMENTAL
Intervention: Irinotecan weekly (125 mg/m²)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irinotecan once every 3 weeks (350 mg/m² or 300 mg/m² for specific patients)
Number of subjects: 0
Study: 11200924

Group type: EXPERIMENTAL
Intervention: Epitril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference brand
Number of subjects: 12
Study: 9059214

Group type: COMPARATOR
Intervention: saline (group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rocuronium 0.1 mg kg‐1 (group R1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rocuronium 0.3 mg kg‐1 (group R3)
Number of subjects: 60
Study: 8437693

Group type: EXPERIMENTAL
Intervention: High-dose piracetam (8 g/d per os)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31448950

Group type: EXPERIMENTAL
Intervention: T'ai chi intervention (n=106)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual medical care control (n=107)
Number of subjects: 213
Study: 28921935

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (proxied by a variant in the ADH1B gene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heaviness of smoking (proxied by a variant in the CHRNA5‐A3‐B4 gene cluster)
Number of subjects: 0
Study: 27217108

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-control exertion
Number of subjects: 0
Study: 24841974

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2 every 3 weeks)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) in EGFR wild-type tumors
Number of subjects: 301

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2 every 3 weeks) in EGFR wild-type tumors
Number of subjects: 301
Study: 22290901

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol + remifentanil
Number of subjects: 366

Group type: COMPARATOR
Intervention: Inhalation anaesthesia with sevoflurane
Number of subjects: 366
Study: 19004511

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg, p.o., o.d. (n=13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 25
Study: 18317188

Group type: EXPERIMENTAL
Intervention: Tantalum implant
Number of subjects: 61

Group type: COMPARATOR
Intervention: Autologous iliac bone graft and plating
Number of subjects: 61
Study: 17182487

Group type: EXPERIMENTAL
Intervention: HAE (hydroalcoholic extract from Punica granatum)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (standard)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study: 14514407

Group type: EXPERIMENTAL
Intervention: Group 1 (1 ‐ 19 years, A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 2 (20 ‐ 50 years, B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal Skin (NS)
Number of subjects: 30
Study: 10807091

Group type: EXPERIMENTAL
Intervention: FLUTTER
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ELTGOL
Number of subjects: 10

Group type: COMPARATOR
Intervention: PD
Number of subjects: 10
Study: 8834341

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GP) 1.0 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol (MP) 15 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of GP 1.0 mg and MP 15 mg (GP+MP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (either drug alone)
Number of subjects: 11
Study: 1572446

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3931899

Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN) for 4 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN) for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enteral nutrition (EN) for nourished patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) for malnourished patients after 4 weeks of PN
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) (weeks 1‐4)
Number of subjects: 32
Study: 30799266

Group type: EXPERIMENTAL
Intervention: 30 5-mg oxycodone immediate-release (OxyIR) pills
Number of subjects: 304

Group type: COMPARATOR
Intervention: 90 5-mg oxycodone immediate-release (OxyIR) pills
Number of subjects: 304
Study: 31006702

Group type: EXPERIMENTAL
Intervention: 540° barbecue rotation (Br540)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 360° barbecue rotation (Br360)
Number of subjects: 60
Study: 26511996

Group type: EXPERIMENTAL
Intervention: 8 mg/kg TCZ+MTX
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: 8 mg/kg TCZ+placebo
Number of subjects: 1162

Group type: COMPARATOR
Intervention: placebo+MTX
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: 4 mg/kg TCZ+MTX
Number of subjects: 1162
Study: 24342385

Group type: COMPARATOR
Intervention: PT + STIM (44.8 ± 14.6 mg/day) + placebo (1.88 mg/day ± 0.72)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: PT + STIM (46.1 ± 16.8 mg/day) + risperidone (1.65 mg/day ± 0.75)
Number of subjects: 168
Study: 22267714

Group type: EXPERIMENTAL
Intervention: Vitamin D3, 50,000 IU administered at 0, 4, and 8 weeks
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 20519376

Group type: EXPERIMENTAL
Intervention: Acute sleep deprivation (SD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline night (control)
Number of subjects: 20
Study: 17106275

Group type: EXPERIMENTAL
Intervention: TMC120 vaginal microbicide gel (various concentrations)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TMC120 vaginal microbicide gel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 64
Study: 16332234

Group type: EXPERIMENTAL
Intervention: Power toothbrush
Number of subjects: 72

Group type: COMPARATOR
Intervention: ADA reference manual toothbrush (control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Experimental manual toothbrush
Number of subjects: 72
Study: 12216014

Group type: EXPERIMENTAL
Intervention: DSM-IV brief psychotic disorder (BPD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Positive schizophrenia (PS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Psychiatrically healthy controls
Number of subjects: 26
Study: 10218041

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment plus miconazole gel and 0.12% chlorhexidine mouthwashes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.05% fluocinonide ointment plus miconazole gel and 0.12% chlorhexidine mouthwashes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (hydroxyethyl cellulose gel plus miconazole gel and 0.12% chlorhexidine mouthwashes)
Number of subjects: 60
Study: 7887796

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 86
Study: 1688495

Group type: EXPERIMENTAL
Intervention: Modified LSA2L2 therapy
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: WBC count < 50 x 10(3)/microL and blasts expressing CD5
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: WBC count < 50 x 10(3)/microL with massive splenomegaly or blasts lacking CD5 expression, or WBC count > 50 x 10(3)/microL with THY antigen expression
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: WBC count > 50 x 10(3)/microL and blasts lacking THY antigen expression
Number of subjects: 253
Study: 358368

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty (SV+P)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10% glucose solution
Number of subjects: 8
Study: 31063156

Group type: EXPERIMENTAL
Intervention: 180mcg/kg/day palifermin for 3 days immediately prior to and after each cycle of alemtuzumab, with repeat doses at M1 and M3.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28237912

Group type: EXPERIMENTAL
Intervention: Left cold caloric vestibular stimulation (CVS) at 4°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right cold CVS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Body temperature/sham CVS
Number of subjects: 0
Study: 25365134

Group type: EXPERIMENTAL
Intervention: Resistance-band protocol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation strength protocol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 23510984

Group type: EXPERIMENTAL
Intervention: Conatumumab 10 mg/kg plus FOLFIRI (Arm A)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ganitumab 12 mg/kg plus FOLFIRI (Arm B)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI (Arm C)
Number of subjects: 155
Study: 21678668

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile saline solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of both groups post-irrigation
Number of subjects: 40
Study: 19551669

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 3 minutes
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 54
Study: 16750696

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study: 14508203

Group type: EXPERIMENTAL
Intervention: Thiazide-based antihypertensive therapy
Number of subjects: 313

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Renal dysfunction group (RD)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Normal renal function group
Number of subjects: 313

Group type: COMPARATOR
Intervention: Overall comparison of RD vs normal group
Number of subjects: 313
Study: 10913471

Group type: EXPERIMENTAL
Intervention: Nurse intervention (30-minute counseling visit at 6-10 days and another 30-minute session 1 month later)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Nurse intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326
Study: 8742561

Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 1441
Study: 1579627

Group type: EXPERIMENTAL
Intervention: Alcohol associated drinks consumed
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-alcohol associated drinks consumed
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alcohol associated drinks held
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-alcohol associated drinks held
Number of subjects: 40
Study: 3893512

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (200 mg thrice daily for 4 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control or placebo
Number of subjects: 9
Study: 31153114

Group type: EXPERIMENTAL
Intervention: NaOCl treatment for 20 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heat treatment (200 °C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NaOCl treatment followed by heat treatment (200 °C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Micro-Raman spectroscopy after NaOCl treatment
Number of subjects: 15